首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Use of Viral Lysate Antigen Combined with Recombinant Protein in Western Immunoblot Assay as Confirmatory Test for Serodiagnosis of Severe Acute Respiratory Syndrome
【2h】

Use of Viral Lysate Antigen Combined with Recombinant Protein in Western Immunoblot Assay as Confirmatory Test for Serodiagnosis of Severe Acute Respiratory Syndrome

机译:病毒裂解液抗原与重组蛋白结合在西方免疫印迹试验中作为严重急性呼吸系统综合症血清诊断的确证试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A Western immunoblot assay for confirmatory serodiagnosis of severe acute respiratory syndrome (SARS) was developed utilizing viral lysate antigens combined with a recombinant nucleocapsid protein, GST-N (glutathione S-transferase-nucleocapsid) of the SARS coronavirus (SARS-CoV). The viral lysate antigens were separated by electrophoresis and transblotted onto nitrocellulose membranes. The resultant membrane was subsequently added with the GST-N recombinant protein at a specific location. The positions of bands corresponding to some of the structural proteins immobilized on the membrane were then located and verified with mouse or rabbit antisera specific to the respective proteins. The Western immunoblot assay was able to detect antibodies to SARS-CoV in all 40 serum specimens from SARS patients and differentiate the SARS-positive samples from those of the healthy donor or non-SARS patient controls (150 samples) when set criteria were followed. In addition, when the immunoblot was used to test samples considered falsely positive by an in-house-developed SARS-specific enzyme-linked immunosorbent assay, band patterns different from those with samples from SARS patients were obtained.
机译:利用病毒裂解物抗原与SARS冠状病毒(SARS-CoV)的重组核衣壳蛋白GST-N(谷胱甘肽S-转移酶-核衣壳)结合,开发了用于严重急性呼吸综合征(SARS)确诊血清学诊断的Western免疫印迹试验。病毒裂解物抗原通过电泳分离,并转移到硝酸纤维素膜上。随后在特定位置向所得膜中添加GST-N重组蛋白。然后定位与固定在膜上的某些结构蛋白相对应的条带位置,并用对相应蛋白特异的小鼠或兔抗血清进行验证。遵循设定标准后,Western免疫印迹分析能够在所有40个来自SARS患者的血清样本中检测到针对SARS-CoV的抗体,并将SARS阳性样品与健康供体或非SARS患者对照(150个样品)区分开。此外,当通过内部开发的SARS特异性酶联免疫吸附测定法将免疫印迹用于检测被认为是假阳性的样品时,可获得与SARS患者样品不同的条带模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号